Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18
March 08 2018 - 06:16PM
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced
today that it will present at Roth Capital Partners 30th annual
growth stock conference on 03/12/18 at 1:30 PM (Laguna Niguel Ritz
Carlton, Salon 6 Yellow)
.
A copy of the presentation materials will be made available on
the company website (www.sorrentotherapeutics.com) following the
event.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its’ extensive immuno-oncology platforms,
including key assets such as fully human antibodies (“G-MAB™
library”), clinical stage immuno-cellular therapies (“CAR-T”),
intracellular targeting antibodies (“iTAbs”), antibody-drug
conjugates (“ADC”), and clinical stage oncolytic virus
(“Sephrevir®”).
Sorrento's commitment to life-enhancing therapies for cancer
patients is also demonstrated by our effort to advance a
first-in-class (TRPV1 agonist) non-opioid pain management small
molecule in Resiniferatoxin (“RTX”) and ZTlido™. Resiniferatoxin is
completing a phase IB trial in terminal cancer patients. ZTlido is
in regulatory review following NDA re-submission.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the expectations for
Sorrento's and its subsidiaries' technologies and product
candidates. Risks and uncertainties that could cause our
actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's and its subsidiaries'
technologies and prospects; risks related to seeking regulatory
approvals and conducting clinical trials; and other risks that are
described in Sorrento's most recent periodic reports filed with the
Securities and Exchange Commission, including Sorrento's Annual
Report on Form 10-K for the year ended December 31, 2016, and
subsequent Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission, including the risk factors set forth in
those filings. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this release and we undertake no obligation to update any
forward-looking statement in this press release except as required
by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (VP Corporate Development)
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.
ZTlido™ and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals, Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.
© 2018 Sorrento Therapeutics, Inc. All Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2023 to Mar 2024